LLY Eli Lilly and Company
Trend channel, buy level and 3-month target. Information only, not financial advice.
Above the channel · 12-month channel rising
Closed above resistance (US$1,332). The fitted trend may no longer apply.
- 18-month channel
- US$1,171 – US$1,333 · rising, +46% a year
- 12-month channel read from
- US$1,167 – US$1,332 · rising, +27% a year
- Price in channel
- 152% (0% = floor, 100% = ceiling)
- Ceiling overhead
- none — above both ceilings
- Turns bearish below
- US$1,167
- Published levels
- Buy and target are not from this channel — see below.
Price history, with the path projected 3 months forward
Updated 3:27 PM ET (20 h ago)
- Daily close
- Upper trend line (18 months)
- Lower trend line (18 months)
- The same lines over the last 12 months
- Dashed after today: projected 3 months
- Our buy
- Our target
Our target
No published call: price has closed 6.4% clear above the channel, so the fitted lines no longer describe where it is Levels below are for reference only.
Buy at or below
US$1,172
level as at 1 Nov 2026
Our target
US$1,367
by 2 Nov 2026
Projected move
16.6%
gross, before costs
Price is at or past our target.
7 settled calls · 6 reached target (85.7%) · average best move 15.3%. See the full record.
- Upper line touches
- 4
- Lower line touches
- 3
- Fit confidence
- 47%
- Fitted
- 1 Nov 2026
Company information
About Eli Lilly and Company
Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza, indicated for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal and various head and neck cancers; Retevmo, used in metastatic NSCLC, medullary thyroid, and other thyroid cancers; Tyvyt for relapsed or refractory classic Hodgkin's lymphoma and non-squamous NSCLC; and Verzenio, prescribed for HR+, HER2- metastatic breast cancer, node-positive, and early breast cancer. For autoimmune and inflammatory conditions, the company markets Olumiant for rheumatoid arthritis, and Taltz, which addresses plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Addressing neurological and pain management needs, Eli Lilly provides Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is available for migraine prevention and episodic cluster headaches, while Zyprexa treats schizophrenia, bipolar I disorder, and aids in bipolar maintenance. Other significant products include Bamlanivimab and etesevimab, along with Bebtelovimab, both developed for COVID-19. Cialis is offered for erectile dysfunction and benign prostatic hyperplasia, and Forteo is available for osteoporosis. Eli Lilly actively engages in strategic collaborations with numerous partners, including Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Established in 1876, Eli Lilly and Company maintains its corporate headquarters in Indianapolis, Indiana.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- David A. Ricks
- Employees
- 50,000
- Country
- US
Scorecard
Our own scores from the fundamentals below (not Morningstar ratings).
- Valuation
- —
- Profitability
- —
- Financial health
- —
- Cash generation
- —
Key statistics
- Market cap
- US$1.18T
- Enterprise value
- —
- Beta
- 0.45
- Avg volume
- 2.63M
- Revenue per share
- —
- Dividend yield
- —
- 52-week range
- 793.82-1292.65
- Exchange
- NYSE
Key ratios
- P/E (TTM)
- —
- PEG
- —
- Price / sales
- —
- Price / book
- —
- EV / EBITDA
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Current ratio
- —
- Quick ratio
- —
- Debt / equity
- —
- Interest cover
- —
Income statement
Balance sheet
Cash flow
Trend lines are fitted to past swing highs and lows and may not continue. Information only, not financial advice.